April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
The Effect Of Peroperative Bevacizumab (Avastin) On Trabeculectomy Outcome: A Prospective, Randomized, Double-blinded, Placebo-controlled Trial
Author Affiliations & Notes
  • Evelien Vandewalle
    Ophthalmology, University Hospitals Leuven, Leuven, Belgium
    Ophthalmology, Lab of Ophthalmology, KULeuven, Belgium
  • Thierry Zeyen
    Ophthalmology, University Hospitals Leuven, Leuven, Belgium
  • Leigh Spielberg
    Ophthalmology, Rotterdam Eye Hospital, Rotterdam, The Netherlands
  • Ingeborg Stalmans
    Ophthalmology, University Hospitals Leuven, Leuven, Belgium
    Ophthalmology, Lab of Ophthalmology, KULeuven, Belgium
  • Footnotes
    Commercial Relationships  Evelien Vandewalle, None; Thierry Zeyen, None; Leigh Spielberg, None; Ingeborg Stalmans, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 625. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Evelien Vandewalle, Thierry Zeyen, Leigh Spielberg, Ingeborg Stalmans; The Effect Of Peroperative Bevacizumab (Avastin) On Trabeculectomy Outcome: A Prospective, Randomized, Double-blinded, Placebo-controlled Trial. Invest. Ophthalmol. Vis. Sci. 2011;52(14):625.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the effect of peroperative intracameral bevacizumab in terms of clinical outcomes following trabeculectomy in patients with either primary open-angle glaucoma (POAG) or normal tension glaucoma (NTG).

Methods: : Between April 2009 until November 2010, 134 consecutive, medically uncontrolled glaucoma patients who were scheduled for first-time trabeculectomy were included in this prospective, randomized, placebo-controlled, double-blinded study. Patients were divided into POAG and NTG groups, which were then randomized to 1 of 2 groups: 50 µl bevacizumab (25mg/ml) or placebo (NaCl). Patients with NTG also received mitomycin C. The target IOP was <18 mmHg for POAG and <14 mmHg for NTG patients.Absolute success was defined as meeting or exceeding the target IOP at the 6-month follow-up period without IOP-lowering medications or postoperative interventions except bleb massage or suturolysis. Qualitative success was defined as meeting the target IOP with IOP-lowering medications or postoperative surgical interventions. Failure was defined as requiring a second trabeculectomy to reach the target IOP.

Results: : As of the end of November 2010, 87 patients had reached the 6-month follow-up point, of whom 45 received bevacizumab and 42 received placebo. Absolute success in this group was 85% in the bevacizumab group and 69% in the placebo group. Qualified success was 13% in the bevacizumab group and 21% in the placebo group. Failure occurred in 2% of the bevacizumab group and 10% of the placebo group. Needlings were performed in 7% of the bevacizumab group and39% of the placebo group.

Conclusions: : A single intracameral injection of bevacizumab at the end of trabeculectomy was associated with increased absolute success rates and reduced need for postoperative interventions in order to reach the target IOP. By May 2011, the complete group will have reached the 6-month follow-up point and the results will be presented with p-values based on a priori calculations of patient inclusion numbers.

Clinical Trial: : https://eudract.ema.europa.eu 2009-009038-33

Keywords: wound healing • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×